Skip to main content
SpringerLink
Log in

Bacteriophage discovery to advance biotechnology and biotherapeutics

  • Genome Watch
  • Published:

From Nature Reviews Microbiology

View current issue Sign up to alerts

This Genome Watch explores how large-scale microbiome studies are facilitating discoveries in bacteriophage biology and functional capabilities that are prime for translation towards advances in biotechnology and biotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Al-Shayeb, B. et al. Clades of huge phages from across Earth’s ecosystems. Nature 578, 425–431 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Adler, B. A. et al. Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing. Nat. Microbiol. 7, 1967–1979 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dedrick, R. M. et al. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin. Infect. Dis. 76, 103–112 (2023).

    Article  PubMed  Google Scholar 

  4. Mu, A. et al. Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection. Microbiome 9, 92 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK

    Andre Mu & Trevor D. Lawley

Authors
  1. Andre Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trevor D. Lawley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andre Mu.

Ethics declarations

Competing interests

T.D.L. is the co-founder and CSO of Microbiotica.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mu, A., Lawley, T.D. Bacteriophage discovery to advance biotechnology and biotherapeutics. Nat Rev Microbiol 21, 279 (2023). https://doi.org/10.1038/s41579-023-00870-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41579-023-00870-w

  • Springer Nature Limited

Search

Navigation